You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm reported $57.8 million in revenues for its Lyra SARS-CoV-2 molecular diagnostic assays in the quarter.
Kantaro said that authorized clinical testing laboratories in Europe can use its enzyme-linked immunoassays, which detect IgG antibodies to two coronavirus antigens.
The collaboration will involve the evaluation of serological tests to detect the durability of patients' immune response to COVID-19.
The test could also be used to assess vaccine effectiveness, should a vaccine become available.
Semi-quantitative SARS-CoV-2 serology tests enable users to measure levels of neutralizing antibodies, but tests need to be more comparable across manufacturers, Siemens said.
Quidel's preliminary earnings more than doubled over the prior quarter on increasing SARS-CoV-2 test sales.
The FDA has authorized the Assure COVID-19 IgG/IgM Rapid Test Device for use on fingerstick blood samples.
The Seattle-based firm believes its novel collection devices are convenient and safe enough to use at home to draw blood for many types of tests.
Comparing the BD and Quidel rapid antigen tests showed they performed similarly despite sensitivity differences in initial FDA filings.
The lateral flow test developed by Mologic to detect IgA, IgG, and IgM antibodies at the point of care has undergone independent validation.